{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055872","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.464035+00:00","generated_at":"2026-06-02T10:43:19.212247+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Crinetics to present initial atumelnant Phase 2 data in CAH and Cushing's at ENDO 2024","bullets":["Five abstracts, four late-breaking, to be presented at ENDO 2024 (June 1-4, Boston).","Initial Phase 2 TouCAHn data: atumelnant shows rapid, profound reductions in androstenedione and 17-hydroxyprogesterone in classic congenital adrenal hyperplasia.","Phase 1b/2a data on atumelnant in ACTH-dependent Cushing's shows first evidence of rapid, sustained cortisol reductions.","Phase 3 PATHFNDR-2 paltusotine data in medically untreated acromegaly patients to be presented; PATHFNDR-1 patient-reported symptoms and long-term safety also featured.","Crinetics plans to submit paltusotine NDA later in 2024; CEO cites major milestone for pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055872","json":"https://secwatch.observer/filing/0000950170-24-055872.json","markdown":"https://secwatch.observer/filing/0000950170-24-055872.md","text":"https://secwatch.observer/filing/0000950170-24-055872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024055872/0000950170-24-055872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024055872/crnx-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:43:19.212247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}